Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Immunomedics, Inc.’s (IMMU - Snapshot Report) fourth quarter 2013 (ended Jun 30) loss of 9 cents per share was narrower than both the year-ago loss and the Zacks Consensus Estimate of loss of 10 cents per share.
.
Total revenues in the final quarter of 2013 were up 41.1% year over year to $1.4 million. The increase was primarily attributable to research and development funding and favorable timing of research activities.

For fiscal 2013, loss was 16 cents per share compared to the year-ago earnings of a penny per share. Loss was narrower than the Zacks Consensus Estimate of a loss of 29 cents per share.

Revenues in fiscal 2013 fell 84.8% year over year to $5.0 million. Revenues in fiscal 2012 benefited from a one-time licensing fee from UCB (UCBJF).

In the fourth quarter of 2013, costs and expenses increased 5.8% to $9 million. The company is currently focusing on the development of its pipeline. Epratuzumab, the most advanced pipeline candidate at Immunomedics, is being evaluated for the treatment of moderate-to-severe systemic lupus erythematosus (SLE).

The company has collaborated with UCB for the candidate. A phase III study on epratuzumab is currently enrolling patients. patient enrollment is expected to continue throughout calendar 2013 with initial results expected in the first quarter of calendar 2015.

The SLE market currently has products like GlaxoSmithKline’s (GSK - Analyst Report) Benlysta.

Another interesting candidate at Immunomedics is clivatuzumab tetraxetan for the treatment of patients suffering from pancreatic cancer. The company expects to initiate a phase III registration trial on the candidate towards the end of calendar 2013 or early 2014.

Immunomedics currently carries a Zacks Rank #3 (Hold). At present, Biogen Idec (BIIB - Analyst Report) looks well-positioned with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%